Compare FMNB & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | DAWN |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.3M | 624.8M |
| IPO Year | N/A | 2021 |
| Metric | FMNB | DAWN |
|---|---|---|
| Price | $14.03 | $8.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $14.50 | ★ $26.56 |
| AVG Volume (30 Days) | 174.8K | ★ 2.8M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ 17.06 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $178,552,000.00 | $133,672,000.00 |
| Revenue This Year | $22.69 | $15.51 |
| Revenue Next Year | $41.03 | $49.99 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | 9.57 | ★ 31.11 |
| 52 Week Low | $11.58 | $5.64 |
| 52 Week High | $16.07 | $14.46 |
| Indicator | FMNB | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 48.23 |
| Support Level | $13.51 | $8.16 |
| Resistance Level | $13.73 | $9.72 |
| Average True Range (ATR) | 0.30 | 0.53 |
| MACD | 0.12 | -0.13 |
| Stochastic Oscillator | 94.05 | 17.45 |
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.